Evidence map›Paper›PMID 39865335›Full record

ReviewArchiv der Pharmazie2025

FDA-approved drugs featuring macrocycles or medium-sized rings.

Youlong Du, Anas Semghouli, Qian Wang, Haibo Mei, Loránd Kiss, Daniel Baecker, Vadim A Soloshonok, Jianlin Han

Abstract readReview
In one paragraph

Review in Archiv der Pharmazie, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Youlong DuJiangsu Co-Innovation Center of Efficient Processing and Utilization of Forest Resources, College of Chemical Engineering, Nanjing Forestry University, Nanjing, China.
Anas SemghouliInstitute of Organic Chemistry, Stereochemistry Research Group, HUN-REN Research Centre for Natural Sciences, Budapest, Hungary.
Qian WangJiangsu Co-Innovation Center of Efficient Processing and Utilization of Forest Resources, College of Chemical Engineering, Nanjing Forestry University, Nanjing, China.
Haibo MeiJiangsu Co-Innovation Center of Efficient Processing and Utilization of Forest Resources, College of Chemical Engineering, Nanjing Forestry University, Nanjing, China.
Loránd KissInstitute of Organic Chemistry, Stereochemistry Research Group, HUN-REN Research Centre for Natural Sciences, Budapest, Hungary.ORCID http://orcid.org/0000-0003-2346-9816
Daniel BaeckerDepartment of Pharmaceutical and Medicinal Chemistry, Institute of Pharmacy, Freie Universität Berlin, Berlin, Germany.ORCID http://orcid.org/0000-0002-1963-9838
Vadim A SoloshonokDepartment of Organic Chemistry I, Faculty of Chemistry, University of the Basque Country UPV/EHU, San Sebastián, Spain.
Jianlin HanJiangsu Co-Innovation Center of Efficient Processing and Utilization of Forest Resources, College of Chemical Engineering, Nanjing Forestry University, Nanjing, China.

Funding

Freie Universität BerlinIkerbasque, Basque Foundation for ScienceNational Natural Science Foundation of China 21761132021National Research, Development and Innovation Office of Hungary NKFIH/DKA K 142266Qing-Lan Project of Jiangsu Province
6 · The paper itself

Abstract

Macrocycles or medium-sized rings offer diverse functionality and stereochemical complexity in a well-organized ring structure, allowing them to fulfill various biochemical functions, resulting in high affinity and selectivity for protein targets, while preserving sufficient bioavailability to reach intracellular compartments. These features have made macrocycles attractive candidates in organic synthesis and drug discovery. Since the 20th century, more than three-score macrocyclic drugs, including radiopharmaceuticals, have been approved by the US Food and Drug Administration (FDA) for treating bacterial and viral infections, cancer, obesity, immunosuppression, inflammatory, and neurological disorders, managing cardiovascular diseases, diabetes, and more. This review presents 17 FDA-approved macrocyclic drugs during the past 5 years, highlighting their importance and critical role in modern therapeutics, and the innovative synthetic approaches for the construction of these macrocycles.

Indexed as

Macrocyclic CompoundsAnimalsDrug ApprovalHumansMolecular StructureUnited StatesUnited States Food and Drug AdministrationMacrocyclic Compoundsasymmetric synthesisdrug design and developmentFDA‐approved drugsmacrocyclic drugspeptides and proteins

Identifiers

PMID39865335
PMCPMC11771699

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.